HOME >> BIOLOGY >> NEWS
Herceptin plus chemotherapy significantly increases disease-free survival in breast cancer

Combining the molecularly targeted therapy Herceptin with chemotherapy in women with early stage breast cancer significantly improves disease-free survival for patients with a specific genetic mutation that results in very aggressive disease, a top UCLA researcher reported Thursday.

Dr. Dennis Slamon, whose laboratory and clinical research lead to the development of Herceptin, reported results of the Phase III study of more than 3,200 women Thursday at the 29th annual San Antonio Breast Cancer Symposium.

The three-armed study compared the standard therapy of Adriamycin and Carboplatin followed by Taxotere (ACT), an experimental regimen of Adriamycin and Carboplatin followed by Taxotere and one year of Herceptin (ACTH), and an experimental regimen of Taxotere and Carboplatin with one year of Herceptin (TCH).

The study tested Herceptin with and without Adriamycin, an anthracycline commonly used to treat breast cancer but one that, when paired with Herceptin, can cause permanent heart damage. Researchers wanted to determine whether they could provide a therapy as effective as ACTH without the resulting cardiac problems. The study, Slamon said, showed that the women who did not receive Adriamycin did just as well as those who did, and they experienced a five-fold decrease in significant heart toxicities compared to those who got Adriamycin. Also, some women in the ACTH arm developed leukemias, while none of the women on the non-Adriamycin arm did, Slamon said.

"This study demonstrates unequivocally that the best treatment for early stage HER-2 positive breast cancer is obtained with a non-anthracycline regimen, TCH, that avoids the significant cardiac damage found when Adriamycin is used with Herceptin," said Slamon, director of clinical/translational research at UCLAs Jonsson Cancer Center. "This trial should impact the way early stage breast cancer is treated, with TCH being considered the preferred option."

H
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
14-Dec-2006


Page: 1 2

Related biology news :

1. Gene profiling predicts resistance to breast cancer drug Herceptin
2. Herceptin plus chemotherapy improves disease-free survival in early breast cancer
3. Nanoparticles carry chemotherapy drug deeper into solid tumors
4. A faster way to recover from chemotherapy and marrow transplant
5. PET accurately identifies esophageal cancer patients positive responses to chemotherapy
6. Combining NSAIDs with chemotherapy, radiation may improve cancer treatment
7. FDG-PET imaging clearly predicts lung cancer patients response to chemotherapy
8. Gene analysis might explain ethnic differences in sensitivity to chemotherapy in lung cancer
9. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs
10. Massive gene screening points way to more effective chemotherapy
11. Researchers find the mechanism by which cells resist chemotherapy

Post Your Comments:
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/15/2014)... 2014  GlassesOff Inc. (OTCBB: GLSO) announced today the ... independent director of the Company,s Board of Directors. ... as its CEO until its acquisition by Stanley ... transaction. Recognized as the inventor of the first Wi-Fi-based ... Wi-Fi -based RFID solutions focused on improving operational efficiency, ...
(Date:12/13/2014)... 2014 /CNW/ - MaRS and Virgin Unite Canada, the non-profit ... joined forces to support Canadian entrepreneurs tackling social and environmental ... was at the MaRS Centre to announce the new partnership, ... fund. This fund has $1 million in seed capital provided ... -based Mindset Social Innovation Foundation, founded by Alison Lawton ...
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses and ... challenges. , The global synthetic biology market is ... Scientific, Inc. (U.S.), DuPont (U.S.), and Royal DSM ... ~65% of the total synthetic biology market. ... @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher Scientific, ...
(Date:12/13/2014)... Research and Markets ( http://www.researchandmarkets.com/research/6p4j9m/glucose_sensors ... "Glucose Sensors: the Next Generation" report to ... The convergence of small-scale electronics ... for a better future to millions of diabetes ... glucose levels accurately and reliably have the capability ...
Breaking Biology Technology:AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3
Cached News: